contained in the test sera. Nevertheless, our findings do not allow to formally exclude a direct impact of IVIg concentration on the performance of our solid-phase assay. Furthermore, IVIg is a heterogeneous product with various effects and possible nonspecific bindings. Disease severity scores, levels of intercellular antibodies, and anti-Dsg-1 or -Dsg-3 IgG4 antibodies decreased during IVIg therapy, showing both laboratory and clinical improvement of the disease (Table 1 and Figure 1) .
Evidence for effects of disease antibodies on apoptotic pathways have been observed in pemphigus. Increased expression of multiple caspases has been detected in lesions of pemphigus patients (Puviani et al., 2003; Wang et al., 2004) . In skin cultures, activation of initiator caspases is seen after treatment with pemphigus IgG (Arredondo et al., 2005; Schmidt et al., 2009) . Furthermore, administration of caspase inhibitors protects mice from developing blisters induced by pemphigus antibodies (Li et al., 2009) , which strongly suggests that caspase activation is critically involved in the formation of acantholysis. Livin and XIAP have similar Baculoviral IAP repeats inhibiting similar caspases and both have a really interesting new gene domain that has a role in protein ubiquitination, which can induce inflammation and immunity. Survivin is structurally different from other IAPs because it lacks the really interesting new gene domain. Survivin is known to function as a major factor in cytokinesis, contributing to the resistance of cancer cells to apoptosis (Richter and Duckett, 2000) .
In summary, we found that serum levels of livin and XIAP increase markedly with IVIg therapy, which is accompanied by a decrease in the levels of pathogenic autoantibodies, as well as disease severity. These results indicate that increase in serum livin and XIAP may be associated with clinical benefits of IVIg. Although the sample size was small, the striking results we report may suggest performing functional studies on the role of IAPs in the mechanism of action of IVIg in preventing acantholysis. In addition, evaluation of IAPs in other IVIg-treated inflammatory disorders is useful in further understanding the mechanism of action of IVIg.
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INK4a cyclin-dependent kinase inhibitor acts as a negative regulator of cyclin D-dependent kinases and is a critical gatekeeper at the G1-S checkpoint (Serrano et al., 1996) . Accordingly, p16 INK4a is frequently inactivated in human tumors, and deletions involving this locus occur frequently in melanomas. Inherited mutations in the p16
INK4a gene are also associated with melanoma susceptibility in 40% of multiple-case melanoma families (Goldstein et al., 2006) . It is generally acknowledged that the progressive and gradual www.jidonline.org 2329 LL Scurr et al. INK4a mutations often develop larger, more numerous, and dysplastic nevi (Bishop et al., 2000) . To precisely examine the expression of p16
INK4a protein in nevi, we initially determined the percentage of nevus cells expressing detectable p16
INK4a in 20 excised human nevi, comprising 15 compound nevi and 5 dysplastic nevi. As shown in Figure 1 , all nevi displayed a heterogenous pattern of p16 INK4a immunopositivity, and although the sample size was small we achieved borderline statistical significance on comparing p16
INK4a expression in compound versus dysplastic nevi (Mann-Whitney test; P ¼ 0.053; Figure 1b) .
Considering that normal melanocytes at the dermal-epidermal junction have undetectable levels of p16
INK4a
(data not shown; Michaloglou et al., 2005) , we sought to determine whether expression of p16
INK4a was actively lost or simply not induced in some nevus cells. During this investigation, we discovered that the p16 INK4a JC8 mouse monoclonal antibody did not detect the melanoma-associated p16
INK4a R24P variant in western and immunohistochemical analysis (Figure 2a and b) . This antibody, which is raised against full-length recombinant p16
INK4a protein, is frequently used for immunohistochemical detection of p16
INK4a in human cancers (Redman et al., 2008) . Using melanocytic nevi from melanoma-prone individuals from a single family (ID 31220) carrying a germline p16 INK4a mutation encoding the R24P variant (Holland et al., 1995) , we were able to examine whether wild-type p16 INK4a expression was selectively lost in nevus cells. In all, 11 nevi (8 compound nevi and 3 dysplastic nevi) were derived from five R24P carriers and 19 nevi (15 compound nevi and 4 dysplastic nevi) were excised from age-matched melanoma-affected controls, with no known family history of melanoma. The nevi ranged in size from 2 to 22 mm for the controls and from 3 to 20 mm for the R24P carriers. The indication for excision was clinical change within a clinically dysplastic (atypical) nevus to exclude melanoma (with low clinical suspicion of malignancy) in the majority of cases.
We used dual immunofluorescence with JC8 and C20 on paraffinembedded sections of nevi; the C20 antibody detects both wild-type and mutant p16
INK4a (Figure 2 ). R24P-positive nevus cells expressing any combination INK4a varied and showed nuclear and cytoplasmic, predominantly cytoplasmic, or predominantly nuclear localization (data not shown). As expected, nearly all p16
-positive control nevus cells stained positively with both the JC8 and C20 antibodies. In contrast, a substantial proportion of nevus cells from R24P carriers showed strong positivity with only the C20 antibody (i.e. no JC8 positivity was seen) (Figure 2c ) and thus, these nevus cells were negative for wild-type p16
INK4a expression. As shown in Figure 2d , there was a highly significant difference between the control nevi and R24P-positive nevi (Mann-Whitney test; Po0.001); in the latter, wild-type p16 INK4a expression was selectively lost in a subset (up to 31%) of nevus cells. These data confirm that the loss of wildtype p16
INK4a expression commences early in melanocyte proliferation, with common benign nevi frequently containing cells with no p16 www.jidonline.org 2331
